TD Cowen analyst Ritu Baral raised the firm’s price target on Sarepta to $175 from $125 and keeps an Outperform rating on the shares. The analyst noted comments suggesitng the FDA s commitment towards the timely advancement and availability of GTx. TD Cowen thinks this bodes well for 9001 s AdComm and odds of accelerated approval by May 29 PDUFA.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- 3 Best Stocks to Buy Now, 3/22/2023, According to Analysts
- Sarepta price target lowered to $200 from $226 at RBC Capital
- Sarepta price target lowered to $165 from $178 at Cantor Fitzgerald
- Sarepta price target lowered to $160 from $200 at Needham
- Sarepta FDA panel switch not a negative, says William Blair
